Baird Medical Investment Holdings Ltd

Baird Medical Investment Holdings Ltd issued a statement addressing recent volatility in its market share price. The company stated it is monitoring the fluctuations and is unaware of any material undisclosed reasons for the decline. Management believes the current market valuation does not accurately reflect the company's business fundamentals and growth potential. Baird Medical reiterated its commitment to its growth strategy and shareholder value. The statement also highlighted the company's progress with its FDA-cleared microwave ablation system for thyroid nodules, expansion of its technology portfolio, adoption by major U.S. institutions, and growing global commercial footprint.

Baird Medical Investment Holdings Ltd (BDMD) filed its 20-F annual report, detailing its completed business combination with ExcelFin Acquisition Corp. The report outlines the corporate structure, regulatory compliance for its microwave ablation medical devices in China, and the ongoing risk related to the Holding Foreign Companies Accountable Act (HFCAA). It also notes the issuance of earnout shares and warrants as part of the business combination, with no cash or asset transfers or dividends paid in 2023-2025.

Baird Medical Investment Holdings Ltd (BDMD) detailed its Business Combination completed on August 3, 2023, which involved Betters Medical contributing Tycoon shares to BDMD and the merger of ExcelFin Acquisition Corp. into a BDMD subsidiary. The transaction included earnout shares for Betters Medical and the Sponsor, contingent on BDMD's ordinary shares reaching $12.50. The company also reported obtaining several Class III medical device registration certificates in 2023-2024 and maintaining its Class II/III medical device manufacture license.

Baird Medical Investment Holdings Ltd. (BDMD) filed its Form 20-F, detailing its business combination completed on August 3, 2023, which involved Betters Medical and ExcelFin. The company, a Cayman Islands holding company, conducts operations through PRC subsidiaries and has secured multiple Class II and III medical device registration certificates and a manufacturing license valid until May 2026. The filing also addresses risks related to its limited operating history, sustainability of gross profit margins, and potential delisting under the HFCAA.